Auricular hypertrichosis (hypertrichosis lanuginosa acquisita, hypertrichosis pinnae auris) is a genetic condition expressed as long and strong hairs growing from the helix of the pinna. Presentation
Ear hair  generally refers to the terminal hair arising from follicles inside the external auditory meatus in humans. In its broader sense, ear hair may also include the fine vellus hair covering much of the ear, particularly at the prominent parts of the anterior ear, or even the abnormal hair growth as seen in hypertrichosis and hirsutism. Medical research on the function of ear hair is currently very scarce. Hair growth within the ear canal is often observed to increase in older men, together with increased growth of nose hair. Excessive hair growth within or on the ear is known medically as auricular hypertrichosis. Some men, particularly in the male population of India, have coarse hair growth along the lower portion of the helix, a condition referred to as "having hairy pinnae" (hypertrichosis lanuginosa acquisita). Genetics
The genetic basis of auricular hypertrichosis has not been settled. Some researchers have proposed a Y-linked pattern of inheritance and others have suggested an autosomal gene is responsible. A third hypothesis predicts the phenotype results from the interaction of two loci, one on the homologous part of the X and Y and one on the nonhomologous sequence of the Y. These hypotheses are not mutually exclusive, and there may be a variety of genetic mechanisms underlying this phenotype. Lee et al.
Nadolol, sold under the brand name Corgard among others, is a medication used to treat high blood pressure, heart pain, atrial fibrillation, and some inherited arrhythmic syndromes. It has also been used to prevent migraine headaches and complications of cirrhosis. It is taken orally.Common side effects include dizziness, feeling tired, a slow heart rate, and Raynaud syndrome. Serious side effects may include heart failure and bronchospasm. Its use in pregnancy and breastfeeding is of unclear safety. It is a non-selective beta blocker and works by blocking β1-adrenergic receptors in the heart and β2-adrenergic receptors in blood vessels.Nadolol was patented in 1970 and came into medical use in 1978. It is available as a generic medication. In 2016, it was the 283rd most commonly prescribed medication in the United States, with more than a million prescriptions. Medical uses
Nadolol is used to treat hypertension and for long-term treatment of angina pectoris and is approved by the FDA for these purposes.It is regularly used off-label for control of heart rate in people with atrial fibrillation, prevention of migraine headaches; prevention of bleeding veins in people with portal hypertension caused by cirrhosis; and to treat people with high levels of thyroid hormone.Nadolol is the preferred beta-blockers in the management of patients with LQTS for prevention of ventricular arrhythmia. It is more efficacious than selective beta blockers or propranolol in the prevention of breakthrough cardiac events.